Show simple item record

dc.contributor.authorGu, X-J
dc.contributor.authorChen, R
dc.contributor.authorSun, C-H
dc.contributor.authorZheng, W
dc.contributor.authorYang, X-H
dc.contributor.authorWang, S-B
dc.contributor.authorUngvari, GS
dc.contributor.authorNg, CH
dc.contributor.authorGolenkov, A
dc.contributor.authorLok, GKI
dc.contributor.authorLi, L
dc.contributor.authorChow, IHI
dc.contributor.authorWang, F
dc.contributor.authorXiang, Y-T
dc.date.accessioned2020-12-21T01:33:25Z
dc.date.available2020-12-21T01:33:25Z
dc.date.issued2018-01-01
dc.identifier.citationGu, X. -J., Chen, R., Sun, C. -H., Zheng, W., Yang, X. -H., Wang, S. -B., Ungvari, G. S., Ng, C. H., Golenkov, A., Lok, G. K. I., Li, L., Chow, I. H. I., Wang, F. & Xiang, Y. -T. (2018). Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 46 (1), pp.22-32. https://doi.org/10.1177/0300060517716783.
dc.identifier.issn0300-0605
dc.identifier.urihttp://hdl.handle.net/11343/256560
dc.description.abstractThis study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. The primary outcome measures were body mass index (BMI) (kg/m2) and body weight (kg). Four RCTs with five study arms were identified and analyzed. Compared with the control group, adjunctive ranitidine was associated with marginally significant reductions in BMI and body weight. After removing an outlier study for BMI, the effect of ranitidine remained significant. Adjunctive ranitidine outperformed the placebo in the negative symptom score of the Positive and Negative Syndrome Scale. Although ranitidine was associated with less frequent drowsiness, other adverse events were similar between the two groups. Adjunctive ranitidine appears to be an effective and safe option for reducing antipsychotic-induced weight gain and improving negative symptoms in patients with schizophrenia. Larger RCTs are warranted to confirm these findings. Trial registration PROSPERO: CRD42016039735.
dc.languageEnglish
dc.publisherSAGE PUBLICATIONS LTD
dc.titleEffect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials
dc.typeJournal Article
dc.identifier.doi10.1177/0300060517716783
melbourne.affiliation.departmentPsychiatry
melbourne.source.titleJournal of International Medical Research
melbourne.source.volume46
melbourne.source.issue1
melbourne.source.pages22-32
dc.rights.licenseCC BY-NC
melbourne.elementsid1224296
melbourne.contributor.authorNg, Chee
dc.identifier.eissn1473-2300
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record